NL-OMON32977撤回不适用
A 12-month Longitudinal, Prospective, Observational, Natural History Study of Patients with Sanfilippo Syndrome Type A (MPS IIIA) - MPS IIIA study
Shire Human Genetic Therapies0 个研究点目标入组 5 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 2 至 99（—）
入选标准
- •1.The patient has a documented deficiency in HNS enzyme activity of *10% of the lower limit of the normal range as measured in fibroblasts or leukocytes (based on normal range for diagnosis of MPS IIIA by a laboratory that is acceptable to Shire HGT).
- •2.The patient has a normal enzyme activity level of at least one other sulfatase (to rule out multiple sulfatase deficiency) as measured in fibroblasts or leukocytes (based on normal range by a laboratory that is acceptable to Shire HGT).
- •3. The patient is * 3 years of age and has a developmental age above 1 year.
- •4. The patient is medically stable, in the opinion of the investigator, to accommodate the protocol requirements, including travel and assessments, without placing an undue burden on the patient/patient's family.
- •5. The patient*s parent(s) or legal guardian(s) has voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent (assent if applicable) form after all relevant aspects of the study have been explained and discussed with the patient*s parent(s), or legal guardian(s). The patient's parents or legal guardian*s consent and patient*s assent as appropriate, must be obtained.
排除标准
- •1. The patient has significant non-MPS IIIA related CNS impairment or behavioral disturbances, which would confound the scientific integrity or interpretation of study assessments, as determined by the Investigator.
- •2. Patients who, for MPS IIIA behavioral-related reasons, in the opinion of the Investigator, would preclude performance of study neurocognitive and developmental testing procedures.
- •3. Patients who are pregnant, or female patients of childbearing potential, who will not or cannot comply with the use of an acceptable method of birth control such as condoms, barrier method, oral contraception, etc.
- •4. The patient is blind and/or deaf.
- •5. The patient has any known or suspected hypersensitivity to anesthesia or is thought to be at an unacceptably high risk for anesthesia due to airway compromise or other conditions.
- •6. The patient or the patient's family has a history of neuroleptic malignant syndrome, malignant hyperthermia, or other anesthesia-related concerns.
- •7. The patient has a history of complications from previous lumbar punctures or technical challenges in conducting lumbar punctures such that the Investigator does not recommend performing lumbar punctures.
- •8. The patient has a history of poorly controlled seizure disorder.
- •9.The patient has a history of an intracranial pressure (ICP) or opening CSF pressure upon lumbar puncture that exceeds the accepted normal limit of 30 cm H2O that has not been definitively treated.
- •10. The patient is currently receiving psychotropic or other medications, which in the Investigator*s opinion, would be likely to substantially confound test results.
- •11. The patient cannot sustain absence from aspirin, non-steroidals, or medications that affect blood clotting within 1 week prior to a relevant study related procedure (eg, lumbar puncture if applicable), or has ingested such medications within 1 week before any procedures in which any change in clotting activity would be deleterious.
- •12. The patient has received treatment with any investigational drug or a device intended as a treatment for MPS IIIA within the 30 days prior to, or during the study, or is currently enrolled in another study that involves an investigational drug or device (enrollment through Safety follow-up contact).
- •13. The patient has received a cord blood or bone marrow transplant.
- •14. The patient*s assent is unattainable, or the patient*s parent(s) or patient*s legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study, or do/does not agree to comply with the protocol defined schedule of assessments.
研究者
相似试验
尚未招募
不适用
A 12-month, non-interventional, observational multinational study to evaluate effectiveness, tolerability, and quality of life of brivaracetam adjunctive therapy in earlier treatment lines in adult patients with history of partial-onset seizures in daily clinical practice.DRKS00025524Parexel International (IRL) Limited (Clinical Research Organisation)600
尚未招募
不适用
A observational study assessing the real world data on inititating treatment of Toujeo after oral antidiabetic drug failure in insulin-naive patients with Type 2 Diabetes Mellitus patients.CTRI/2018/02/012158Sanofi India Limited
已完成
不适用
A Prospective Longitudinal Observational Study of Clinical Outcomes, Adverse Events, and Secondary Malignancies After Definitive Radiotherapy for Breast Cancer PatientsBreast CancerJPRN-UMIN000034530The University of Tokyo4,000
进行中（未招募）
1 期
A study aiming to collect data and provide a better understanding of the long-term outcome of imlifidase in treatment of immunological graft rejection in kidney transplant patientsAntibody-mediated rejection in kidney transplant patientsMedDRA version: 20.0Level: PTClassification code 10023439Term: Kidney transplant rejectionSystem Organ Class: 10021428 - Immune system disordersEUCTR2020-004777-49-ATHansa Biopharma30
尚未招募
不适用
Comparison of suspected or negative cases with confirmed cases of COVID-19 at Max HospitalCTRI/2020/04/024772Max Healthcare A Unit of Devki Devi Foundation